Newsletter

You are here

Fundamental research

28 - 06 - 2017

Preclinical research should no longer favour the male sex

Preclinical studies in vitro and in vivo give a high priority to the male sex which makes the results of the studies less transferable to women. Large institutes such as the NIH have been demanding since 2014 that the male and female sexes be studied equally.

One study sought to find out more and examined the expression by sex of KO mutations (inhibition of a gene) in mice. Of the more than 2000 mutations examined, sex affects 10% to 50% depending on whether the mutation concerns qualitative or quantitative data.

There is no longer any doubt, good preclinical research must study both sexes.